In a crossover study 32 patients with hypertension were randomly allocated to treatment with spironolactone 200 mg/day for two months, propranolol 320 mg/day for two months, and a combination of both drugs at half the dose. Between the treatments placebo was given for two months. Both spironolactone and propranolol lowered the blood pressure significantly in both positions.
primary adrenocortical insufficiency7 8 but not for secondary adrenocortical insufficiency because of the possibility of a preserved normal adrenocortical function in secondary insufficiency. Nevertheless, we have recently shown in glucocorticoid-treated patients the value of the simple ACTH stimulation test in assessing the integrated HPA function in secondary insufficiency. 3 We compared the result of the simple ACTH stimulation test with the HPA response to insulin hypoglycaemia in patients with or without hypothalamic-pituitary disease and varying degrees of adrenocortical insufficiency. A very close correlation was found between the peak plasma cortisol after ACTH and after insulin hypoglycaemia in each patient. It should be emphasised that a patient with borderline results on one test will also have borderline results on the other test, indicating that a borderline ACTH test result should be followed by further evaluation of the HPA function. Our results suggest that a definitely normal response to ACTH is most unlikely to coexist with an impaired response to insulin hypoglycaemia. Examples of such a discrepancy have been reported,2 9 but information on whether both sweating and low blood glucose values were obtained during insulin hypoglycaemia was not given.
In conclusion, our 
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The initial plasma renin activity (PRA) levels ranged from 0 4 to 5-0 jig angiotensin I 1-1 h-', and there was a close correlation between these levels and the effects of the drugs: with increasing PRA the response to propranolol was better while the opposite was true for spironolactone. Spironolactone reduced the blood pressure more at eight than at four weeks, while no such difference could be shown for propranolol. 
Patients and methods
Thirty-two consecutive outpatients with hypertension, 14 men and 18 women ranging in age from 27 to 62 years (mean 46), entered the 10-month trial. The average known duration of hypertension was [3] [4] years (range 0-20); 23 patients had grade I hypertension (World Health Organisation classification) and nine had grade II hypertension. None had eye-ground changes worse than grade II. Nineteen patients had never received antihypertensive treatment, and in the remaining 13 all medication had been withdrawn for at least four weeks. No patients with obstructive lung disease, diabetes mellitus, or hepatic or renal disorder were admitted. None had malignant or secondary hypertension. All had a mean untreated blood pressure above 160/100 mm Hg supine and standing during the run-in period.
Examination included a 12-lead electrocardiogram, chest x-ray examination, and either isotope renography, rapid-sequence intravenous pyelography, or renal arteriography. Urinary adrenaline and noradrenaline levels were measured before treatment. Venous samples for measuring PRA were drawn between 9 am and noon after at least three hours of ambulation. PRA was determined by radioimmunoassay of angiotensin I (AI) according to the method of Haber et al8 with reagents from New England Nuclear Laboratories, but pH was adjusted to 6 0. The serum and urinary concentrations of sodium and potassium were determined by flame photometry, serum calcium concentrations with a complexometric method,9 and serum urea concentrations with a diacetylmonoxime method.'0 Serum determinations were performed with the SMA 12/60 from Technicon.
Plasma aldosterone levels were determined by a highly sensitive, reproducible, and specific direct radioimmunoassay" on the same samples as were used for PRA determinations. Each period consisted of eight weeks of active treatment followed by eight weeks on placebo tablets identical to those containing the previous drug. During the first active period patients received either propranolol 160 mg twice daily (group 1) or spironolactone 100 mg twice daily (group 2). Spironolactone was given in full dose from the beginning, while the dose of propranolol started with 40 mg twice daily and was increased during the first week. After the treatment and subsequent placebo period had been completed for each drug the patients were given combined treatment with half the dose of the two drugs for another two months. The allocation to either treatment was randomised and patients were not aware of the type of treatment given.
Patients were seen every fourth week at the same time of the day (9 am-12 am). Specially trained nurses, unaware of the treatment given, measured blood pressure after 10 minutes of supine rest and after two minutes of standing. A mercury manometer was used in a quiet room and the diastolic pressure registered at the disappearance of the Korotkoff sounds (fifth phase). Blood pressure levels were the mean of at least two recordings and adjusted to the nearest 5 mm Hg. The regular four-weekly measurements minimised possible changes in laboratory values, particularly PRA, and blood pressure in women with regular menstrual cycles. At each visit the patients were examined by one of us and followed by the same doctor throughout the whole study.
Statistical methods-The Spearman rank test and correlation coefficient were used to evaluate the relation between differences in decreases of blood pressure and the initial PRA levels.'2 The differences were assumed to be linearly related to the logarithm of initial PRA in order to find the PRA values without significance for the therapeutic response. Regression analysis was then applied." Student's t test was also used. Values are given as means ± SE of mean.
Results
Twenty-seven patients completed the study. All patients had normal serum potassium levels and normal kidney function. Plasma aldosterone values were normal (137-988 pmol/l (50-356 ng/l)). Conversion: SI to traditional units-Sodium 1 mmol/l = 1 mEq/l. Potassium: 1 mmol/l = 1 mEql. Urea: 1 mmol/l 6 mg/100 ml. Calcium: 1 mrnol/l z 4 mg/100 ml.
1-l h-1 (range 0-1-2-0), while on spironolactone it rose to 6-1 ,ug AI 1-l h-l (range 1-1-17-0) ( 
WITHDRAWALS AND SIDE EFFECTS
Five patients had to be withdrawn from the study. One patient had a suspected but not verified hypertensive crisis when on propranolol.
Another was lost to follow-up when he left the area. One man was excluded because of suspected phaeochromocytoma (occasionally raised levels of urinary catecholamines), which was not verified at surgery. Two patients failed to attend for all examinations.
Both drugs were well tolerated despite the rather high doses given. No patient was withdrawn from the study because of side effects. Those that occurred were of only minor clinical importance on propranolol, insomnia (2), paresthesiae (2), diarrhoea (1), and facial oedema (1); on spironolactone, impotence (2), rash (2), and diarrhoea (1 Both propranolol and spironolactone have a considerable effect on the renin-angiotensin-aldosterone system. 24 The two drugs act mainly antagonistically on this system: propranolol consistently lowers PRA2 5while spironolactone increases it. These effects on PRA are unrelated to the changes in blood pressure.
It has been suggested that constructing profiles of the PRA and aldosterone secretion rate of hypertensive patients might have both prognostic and therapeutic implications.' Although the renin-angiotensin-aldosterone system is known to be implicated in most types of secondary hypertension, its pathogenetic role in primary hypertension remains obscure.24
The response to beta-adrenergic blocking drugs has been unrelated to pretreatment PRA levels in some studies.4 2627 Biihler et al3 reported a good response to propranolol in patients with normal or high PRA. They also showed a relation between the decrease of renin and the fall in blood pressure. We observed a significant correlation between the initial PRA and the hypotensive action of propranolol-that is, the higher the PRA the greater the reduction in blood pressure. No such relation could be shown between the decrease in PRA during treatment and the fall in blood pressure, and no difference was found between the blood pressure at four and eight weeks.
In most patients with low-renin hypertension spironolactone has a hypotensive effect. 5 6It has been argued that spironolactone and diuretics exert comparable actions in these patients.7 2* Spark et a129 showed that spironolactone was more effective than hydrochlorothiazide in low renin hypertension. Brunner et a12 could find no significant effect of propranolol in low-renin hypertension. We have made the same observation in 25 patients with low and non-responsive PRA (unpublished data). Our results showed that spironolactone had a favourable effect at low renin levels, while the opposite was true for propranolol. The blood pressure reductions were well correlated to pretreatment PRA levels. The correlation was validated by the fact that the initial PRA was regained during placebo. Prolonged treatment (more than four weeks) with spironolactone seems necessary to obtain a full effect since blood pressure was lower after eight weeks than after four. It should thus be emphasised that the duration of treatment with spironolactone must be at least eight weeks to evaluate the full hypotensive properties of the drug. We also confirmed that both propranolol and spironolactone were effective in moderate hypertension. Hunyor et a128 reported only a slightly hypotensive effect during treatment for one month with spironolactone in very mild hypertension.
A synergistic effect on blood pressure was achieved with the combination of propranolol and spironolactone in only half the doses used in the single drug periods. The additional decrease in blood pressure was obvious and this effect was unrelated to the initial PRA. The combination treatment was well tolerated.
Using PRA concentrations to select the best antihypertensive treatment would be desirable, especially when single-drug treatment is wanted. Nevertheless, the combined treatment gave an excellent antihypertensive effect in all our patients. This indicates that a trial and error management might still be justified. If PRA cannot be measured routinely we recommend that when the fall in blood pressure is unsatisfactory on a renindepressing beta-blocker-for example, propranolol-a volumedepleting drug such as spironolactone or a thiazide should be used either separately or, if further effect is needed, in combination with propranolol. In the same way, starting with a volume-depleting drug, the pressure effect can be enhanced by I~~~~ adding a renin-depressing agent. The range where the pressure effect of the two drugs was uncorrelated to the PRA-levels (1-0-2 0 fig AI 1-' h-1 ) might represent the normal range of PRA.
We conclude from this controlled investigation with propranolol and spironolactone in primary hypertension that both drugs have valuable antihypertensive properties, but their combination results in a further reduction in blood pressure. Our findings also support the concept that patients with high renin concentrations respond more favourably to beta-blocking agents-that is, propranolol-and that those with low renin concentrations respond better to spironolactone. The data also suggest that the renin-angiotensin-aldosterone system may be implicated in primary hypertension.
Introduction
The comfort given by support hosiery, and any possible therapeutic effect on varicose veins is related to the pressure exerted on the legs.' A variety of garments is available, ranging from heavyweight elastic stockings to cosmetically acceptable nylon and elastane hosiery. This study measures the support given by different types of hosiery. Few studies of compression have been undertaken either by manufacturers concerned with establishing the correct design and strength of hosiery2 or in the course of clinical studies where it was necessary to describe a particular garment. Meyerowitz and Crook3 used a small, airfilled bag to measure, at calf level, the compression provided by one-way stretch elastic stockings. Makin et a14 measured the Consideration of the efficacy of different support garments suggested that we needed to study not only the compression exerted on the leg but also the ability of the hosiery to limit the distension of varicose veins. The pressure which a garment exerts on the leg will depend on both its tension and the radius of the limb at a given level. The tension depends on the elasticity of the material and the way it is made. The Laplace relationship states that compression (P) is inversely proportional to radius (R) for a constant rension (T) (P = T/R). Thus, a decrease in the radius over which the tension of the garment is acting will give an increase in compression. It follows that the compression exerted by hosiery on a distended varicose vein, with a radius of curvature much smaller than that of the whole limb, will be proportionately greater than the compression exerted on the limb at that level. The effect of this compression may be deduced from an examination of the pressure-volume relationship of a varicose vein when it is supported by hosiery, and from measurements of the reduction in volume of blood which collects in varicose veins when they are supported by hosiery and exposed to various distending pressures.
Two methods of measuring support were devised: firstly, compression was measured by a large, flat, liquid-filled bag; secondly, a model varicose vein was constructed so that an estimate of the pressure-volume relationship of a distended superficial vein under hosiery could be made without the difficulties associated with measuring a real vein.
Materials and methods
Five types of two-way stretch garments were selected for the tests: (a) 250-denier, nylon-covered, elastane support tights; (b) nyloncovered, 0-3-mm rubber core, National Health stockings; (c) 115-denier, nylon-covered elastane support stockings; (d) 115-denier,
